Participated · Seed · Jul 2026

Marquee provides an AI-driven scouting and recruitment platform used by football recruitment departments to find targets, read full player reports, build shortlists, shape shadow squads and compare preferred targets by position. Users reportedly stay in the product to conduct workflows end-to-end rather than merely running searches, with the platform informing decisions about whom to watch live. The company says feedback from sporting directors and technical evaluators highlights the depth and reliability of its reports. Marquee emphasizes enabling teams to finish the week further ahead while retaining human judgement. Following the seed raise, Marquee plans to accelerate building and expand the platform with the newly raised capital. No revenue, user counts, founding year or location details were provided in the announcement.

Participated · Series A · Feb 2023

MDI Health offers an autonomous, hyper-personalized AI medication management platform that analyzes thousands of factors to identify medication-related risks and provides recommendations in minutes instead of hours. The platform equips clinicians, payers and pharmacies to perform comprehensive medication reviews, reduce adverse drug events and improve outcomes. MDI positions its solution as an alternative to alert-based medication management tools that require laborious processes. The company cites medication-related harms as a major driver of costs and mortality and targets cost savings and improved health outcomes at scale. MDI plans to use new funding to meet rising customer demand and to scale its U.S. and Israeli R&D teams to drive product development. The company was founded in 2019 and is based in Los Angeles; its disclosures state U.S. medication-related costs total $528 billion annually.

Led · Seed · Mar 2022

Behavidence develops machine learning-based tools to detect and assist with remote monitoring and management of mental health conditions such as depression, anxiety and ADHD via passive digital biomarkers. Its products are positioned for measurement-based outcomes including monitoring employee burnout and stress, predicting relapse, screening, and remote monitoring for clinical interventions and comorbid conditions. The company says its digital solutions have been adopted by health organizations, tech, commercial and government entities. Behavidence has secured more than $1 million in contracts with customers across the United States, Europe, Africa and Asia. Named clients include the Department of Veterans Affairs, Discovery Health Insurance and Essen Health Care. The company plans to use new funding to further develop its machine learning tools.

Led · Seed · Jan 2022

Quris is a dual‑headquartered (Boston and Israel) AI company operating a Bio‑AI Clinical Prediction Platform to better predict which drug candidates will safely work in humans. It uses a patented Chip‑on‑Chip technology to test thousands of known and novel drug candidates on hundreds of genetically diverse, miniaturized patients‑on‑a‑chip. Its automated, self‑training BioAI platform generates proprietary data and applies machine learning to quickly predict clinical safety and efficacy, with applications in new drug development, repurposing, and personalization. Quris positions this approach to avoid the tremendous costs of failed clinical trials and accelerate selection of candidates for clinical testing. The company plans to scale to rapidly scan hundreds of drug candidates to further train its AI engine, expand its team, and build partnerships as it prepares its lead discovery for clinical testing. Quris is backed by strategic biotech and big‑data investors and is led by a team of AI and medical research specialists. Quris combines linked organ‑on‑a‑chip organoid systems with machine learning to simulate human physiology at scale, enabling faster, cheaper preclinical testing without mice. Its "chip‑on‑chip" serial organoid approach uses less biological material and automation to run many simulated humans at a fraction of the cost of academic setups. The company trains AI models on experimental data to interpret multi‑organ signals and prioritize drug candidates, aiming to replace large animal cohorts with dozens-to-hundreds of automated tests. Quris has an agreement with the NY Stem Cell Foundation for stem cell workflow access and lists Robert Langer and Nobel laureate Aaron Ciechanover on its advisory roster. It pursues two business lines: a results‑contingent screening service for pharma and internal drug development; the company is advancing a Fragile X treatment toward clinical testing next year. CEO Isaac Bentwich says the technology supports more personalized medicine and that initial funding will productize the setup and train the AI on the first hundreds-to-thousands of drugs.

Led · Seed · Oct 2021

X-trodes is a Tel Aviv-based bio-convergence company that developed wearable technology for advanced electrophysiological measurement and analytics. It created the world’s first scalable wireless Smart Skin, a wearable platform designed to monitor patients in their natural environment. The company is bringing two initial products to market: a medical-grade wireless sleep monitoring system for neurological and psychiatric disorders and a flexible muscle recovery wearable that monitors electrophysiology and provides AI-driven, wireless analytics. X-trodes’ single-patch multi-modality measurement retrieves meaningful insights and diagnostics from patients in their own beds and delivers AI-driven analysis for dynamic muscle monitoring. The company raised $4.5M in seed funding to support its go-to-market and product development efforts. Led by co-founder and CEO Ziv Peremen, X-trodes has 12 employees and is focused on scaling its Smart Skin platform.